Journal of Asthma and Allergy最新文献

{"title":"Benralizumab Outcomes in Patients with Severe Eosinophilic Asthma Treated in Real-Life Settings: Results of the BREEZE Study in 5 Countries From Central Eastern Europe and Baltics.","authors":"Florin Mihaltan, Zsuzsanna Csoma, Norbert Pauk, Béla Irás, Jūratė Baukienė, Gabriela Teodorescu, Kęstutis Malakauskas, Maria Staevska","doi":"10.2147/JAA.S503048","DOIUrl":"10.2147/JAA.S503048","url":null,"abstract":"<p><strong>Purpose: </strong>To describe real-world clinical characteristics, treatment patterns and outcomes of severe eosinophilic asthma (SEA) patients initiated on benralizumab after treatment authorization in Central Eastern Europe and Baltic Area.</p><p><strong>Patients and methods: </strong>BREEZE was a retrospective, medical chart review with a pre-post design conducted in 42 clinical centers from Bulgaria, Czech Republic, Hungary, Lithuania and Romania. Eligibility included diagnosis of SEA and at least one dose of benralizumab administered in real-life settings. Descriptive statistics were used in the full analysis set and key subgroups stratified by blood eosinophils (bEOS) number, maintenance oral corticosteroids (mOCS) use and prior biologics exposure and included calculation of the annualized exacerbation rate (AER) at baseline, and weeks (W) 16 and 48.</p><p><strong>Results: </strong>Of 381 patients included, 66% were female with overall mean age 56 ±12 years at benralizumab start. At baseline: median bEOS 580 cells/μL (74% bEOS>400), forced expiratory volume in 1 second (FEV₁) 1660 mL, mOCS use in 25% of patients (10 mg/day prednisone equivalent, 68% >5 mg/day), AER 3.05 (95% CI 2.9-3.2), and poorly controlled asthma (Asthma Control Test [ACT] <16) in 63% of patients. Median duration of exposure to benralizumab was 11.5 (95% CI 7.7-12.3) months, and discontinuation rate was 1.3% (95% CI 0.4%-3.0%). Median bEOS decreased to 0 at W16 and maintained thereafter; FEV₁ increases of +240 mL at W16 and +335 mL at W48 were reported (p <0.001 for both). Overall relative reduction in AER at W16 and W48 was 92% and 93%, respectively, and 82-94% across key subgroups. mOCS dose reduction was 50%, and proportion of patients requiring >5 mg/day decreased constantly (25% at W16, 28% at W48). ACT scores increased from W16 to W56 (p <0.001 for all).</p><p><strong>Conclusion: </strong>Our findings indicate clinically meaningful benefits of benralizumab across multiple geographies and various subgroups of patients with SEA.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"18 ","pages":"195-210"},"PeriodicalIF":3.7,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11844207/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143483276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Economic Evaluation of Mepolizumab as Add-on Therapy to Standard Care in Severe Eosinophilic Asthma: A Cost-Effectiveness Analysis in Colombia.","authors":"Jefferson Antonio Buendia, Ranniery Acuna-Cordero, Carlos E Rodriguez-Martinez","doi":"10.2147/JAA.S502216","DOIUrl":"10.2147/JAA.S502216","url":null,"abstract":"<p><strong>Background: </strong>Mepolizumab, an IL-5 receptor antagonist, is a targeted therapy approved for treating severe eosinophilic persistent asthma. While it offers significant clinical benefits in reducing exacerbations and improving quality of life, its high cost raises concerns about its affordability and overall value in resource-constrained settings. This study evaluates the cost-effectiveness of adding mepolizumab to standard care (SoC) compared to SoC alone in adolescents and adults with severe, uncontrolled eosinophilic asthma in Colombia.</p><p><strong>Methods: </strong>We used a Markov model with a societal perspective and a lifetime horizon to estimate costs and quality-adjusted life years (QALYs). Parameters were derived from local data and existing literature. Both deterministic and probabilistic sensitivity analyses were performed to test the model's robustness. Cost-effectiveness was assessed using a willingness-to-pay threshold of US$5,130.</p><p><strong>Results: </strong>Mepolizumab demonstrated an additional 0.31 QALYs per patient compared to standard of care (SoC), with an incremental cost-effectiveness ratio (ICER) of US$25,210 per QALY gained. Sensitivity analyses showed that the price of mepolizumab was the key driver of cost-effectiveness. Over a 5-year horizon, adding mepolizumab to SoC would have a significant budgetary impact. These findings highlight the need to balance clinical benefit with affordability in resource-limited settings.</p><p><strong>Conclusion: </strong>Although mepolizumab improves patients' quality of life, it is not considered cost-effective in Colombia under the conditions of this study. The results provide valuable information for policymakers to consider when refining local clinical practice guidelines.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"18 ","pages":"211-218"},"PeriodicalIF":3.7,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11844197/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143483277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Role of Allergenic Components in Children with House Dust Mite-Induced Allergic Diseases.","authors":"Qiuyan Xu, Yunxia Shang, Xiang Li, Shuangqin Ran, Min Lu, Lei Cheng","doi":"10.2147/JAA.S505471","DOIUrl":"10.2147/JAA.S505471","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the main characteristics of HDM-induced allergic diseases in children and to explore allergen component-specific sensitization patterns, features, and correlations with clinical symptoms.</p><p><strong>Methods: </strong>Serum samples were collected from children with HDM-induced allergic diseases. Information on age, sex, and clinical symptoms was recorded. A protein chip method was used to detect specific IgE (sIgE) against HDM components, including <i>Der p</i> 1, <i>Der f</i> 1, <i>Der p</i> 2, <i>Der f</i> 2, <i>Der p</i> 5, <i>Der p</i> 7, <i>Der p</i> 10, <i>Der p</i> 21, and <i>Der p</i> 23.</p><p><strong>Results: </strong>116/120 (96.67%) exhibited positive reactions to HDM components. The highest positive rates were for <i>Der p</i> 1 (95.83%) and <i>Der f</i> 1 (95.83%), followed by <i>Der p</i> 2 (86.67%), <i>Der f</i> 2 (85.83%), and <i>Der p</i> 23 (62.50%). <i>Der p</i> 5, 7, and 23 positivity increased with age. Notably, <i>Der p</i> 23 positivity was higher in the allergic asthma (AA) group than in the non-AA, atopic dermatitis (AD), and allergic rhinitis (AR) groups and higher in AR with AA than AR-only. <i>Der p</i> 2 and <i>Der f</i> 2 had higher positive rates in respiratory allergies than in AD alone. The impact of other HDM components on different allergic diseases was minimal. Pearson correlation analysis demonstrated strong positive correlations between sIgE concentrations for various HDM components, especially between <i>Der p</i> 2 and <i>Der f</i> 2 (r = 0.96, p < 0.01).</p><p><strong>Conclusion: </strong><i>Der p</i> 1, <i>Der f</i> 1, <i>Der p</i> 2, <i>Der f</i> 2, and <i>Der f</i> 23 are the major allergens, with <i>Der p</i> 5, 7, and 23 showing age-specific sensitization patterns. <i>Der p</i> 2 and <i>Der f</i> 2 are closely associated with respiratory allergies, whereas <i>Der p</i> 23 is particularly linked to the development of asthma. There is a general positive correlation among the sIgE concentrations of various HDM components.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"18 ","pages":"183-193"},"PeriodicalIF":3.7,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11832350/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143449099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Characteristics of 31 Patients with Chest Pain Variant Asthma.","authors":"Wenping Mao, Yanli Gao, Wanlu Sun, Jie Li, Jing Wang, Zhaomei Wang, Liming Zhang, Kewu Huang","doi":"10.2147/JAA.S494385","DOIUrl":"10.2147/JAA.S494385","url":null,"abstract":"<p><strong>Purpose: </strong>Asthma is a major public health challenge in China. Although chest pain variant asthma (CPVA) is not common in clinical practice, there are still a few people who only or mainly manifest as chest pain. Here, we aim to introduce the characteristics of their symptoms, lung function and chest imaging features to arouse the attention of physicians to know better of the disease.</p><p><strong>Patients and methods: </strong>We retrospectively analyzed thirty-one patients who had been diagnosed with CPVA based on clinical data and positive bronchial provocation tests (BPTs).</p><p><strong>Results: </strong>The mean age of all enrolled patients was forty-seven years, and females accounted for 64.5%. Main features of chest pain manifested as dull pain and mild pain with unfixed location, and several patients were presented with distending pain, pinprick pain, chest pain related to breathing, chest pain position-related and chest pain like angina pectoris. The median duration of their chest pain was four months, and 77.4% of the patients did not find any trigger. Among the 31 patients, 10 were with normal lung function, 14 were with mild obstructive ventilation dysfunction, 6 were with small airway dysfunction and 1 was with mild restrictive ventilation dysfunction. The predicted values of forced expiratory volume in 1 s (FEV₁) were greater than 80% in 29 out of 31 patients, and the values of other two patients were 74% and 79%, respectively. Additionally, 35.5% of the patients meanwhile had allergic rhinitis, and 64.5% of the patients exhibited type 2 inflammation. Among the 31 patients, 22 (71.0%) showed abnormalities on inspiratory computed tomography (CT) scans, including bronchiolar (38.7%), bronchial (25.8%) or pulmonary parenchyma abnormalities (32.3%). Only 7 patients (22.6%) had normal inspiratory CT scans.</p><p><strong>Conclusion: </strong>CPVA is relatively rare in clinical practice. Understanding its manifestations, lung function, chest CT features and comorbidities is helpful for diagnosis and evaluation of patients with such symptoms.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"18 ","pages":"173-182"},"PeriodicalIF":3.7,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11827699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Computational Phenotyping of Obstructive Airway Diseases: A Systematic Review.","authors":"Muwada Bashir Awad Bashir, Gregorio Paolo Milani, Valentina De Cosmi, Alessandra Mazzocchi, Guoqiang Zhang, Rani Basna, Linnea Hedman, Anne Lindberg, Linda Ekerljung, Malin Axelsson, Lowie E G W Vanfleteren, Eva Rönmark, Helena Backman, Hannu Kankaanranta, Bright I Nwaru","doi":"10.2147/JAA.S463572","DOIUrl":"10.2147/JAA.S463572","url":null,"abstract":"<p><strong>Introduction: </strong>Computational sciences have significantly contributed to characterizing airway disease phenotypes, complementing medical expertise. However, comparing studies that derive phenotypes is challenging due to varying decisions made during phenotyping. We conducted a systematic review to describe studies that utilized unsupervised computational approaches for phenotyping obstructive airway diseases in children and adults.</p><p><strong>Methods: </strong>We searched for relevant papers published between 2010 and 2020 in PubMed, EMBASE, Scopus, Web of Science, and Google Scholar. Additional sources included conference proceedings, reference lists, and expert recommendations. Two reviewers independently screened studies for eligibility, extracted data, and assessed study quality. Disagreements were resolved by a third reviewer. An in-house quality appraisal tool was used. Evidence was synthesized, focusing on populations, variables, and computational approaches used for deriving phenotypes.</p><p><strong>Results: </strong>Of 120 studies included in the review, 60 focused on asthma, 19 on severe asthma, 28 on COPD, 4 on asthma-COPD overlap (ACO), and 9 on rhinitis. Among asthma studies, 31 focused on adults and 9 on children, with phenotypes related to atopy, age at onset, and disease severity. Severe asthma phenotypes were characterized by symptomatology, atopy, and age at onset. COPD phenotypes involved lung function, emphysematous changes, smoking, comorbidities, and daily life impairment. ACO and rhinitis phenotypes were mostly defined by symptoms, lung function, and sensitization, respectively. Most studies used hierarchical clustering, with some employing latent class modeling, mixture models, and factor analysis. The comprehensiveness of variable reporting was the best quality indicator, while reproducibility measures were often lacking.</p><p><strong>Conclusion: </strong>Variations in phenotyping methods, study settings, participant profiles, and variables contribute to significant differences in characterizing asthma, severe asthma, COPD, ACO, and rhinitis phenotypes across studies. Lack of reproducibility measures limits the evaluation of computational phenotyping in airway diseases, underscoring the need for consistent approaches to defining outcomes and selecting variables to ensure reliable phenotyping.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"18 ","pages":"113-160"},"PeriodicalIF":3.7,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11809425/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Burden and Healthcare Resource Use of Asthma in Children in the UK.","authors":"Imène Gouia, Florence Joulain, Yi Zhang, Christopher Ll Morgan, Asif H Khan","doi":"10.2147/JAA.S452747","DOIUrl":"10.2147/JAA.S452747","url":null,"abstract":"<p><strong>Background: </strong>UK pediatric asthma prevalence is among the highest in Europe, and although the clinical and economic burden of asthma in UK adults is well described, childhood asthma data is lacking. We assessed the clinical and economic burden of asthma in children in the UK to better understand the impact of pediatric asthma.</p><p><strong>Methods: </strong>This was a retrospective, case-matched, longitudinal analysis using the Clinical Practice Research Datalink GOLD database and linked patient-level data (Hospital Episode Statistics and Office for National Statistics datasets) of selected patient (aged 6-11 years) records in 2017. Severe exacerbation and re-exacerbation rates per patient-year (PPY), all-cause healthcare resource utilization (HCRU), and HCRU-related costs were assessed in asthma patients versus matched non-asthma controls, stratified by severity.</p><p><strong>Results: </strong>Among 5950 patients, severe exacerbation rate was 0.06, 0.17 and 0.31 PPY for mild, moderate, and severe asthma, respectively. Incident rate of severe exacerbations were higher for moderate asthma (incident rate ratios [IRR; 95% CI] 2.87 [2.30-3.56], <i>P</i><0.0001) and severe asthma (5.19 [4.20-6.41], <i>P</i><0.0001) versus mild asthma. Risk of re-exacerbation was significantly increased for severe versus mild asthma (hazard ratio [95% CI]: 2.98 [1.90-4.65], <i>P</i><0.001). All-cause HCRU (IRR [95% CI]) was higher in severe asthma patients versus controls (primary care: 3.81 [3.54-4.09], <i>P</i><0.0001; inpatient admissions: 3.23 [2.31-4.62], <i>P</i><0.0001]); total-cost ratios relative to controls for mild, moderate, and severe asthma were 1.58 (1.39-1.78, <i>P</i><0.0001), 2.56 (1.97-3.33, <i>P</i><0.0001), and 3.42 (2.54-4.61, <i>P</i><0.0001), respectively. Asthma-related costs increased with severity (total-cost ratios: moderate versus mild, 1.68 [1.45-1.97], <i>P</i><0.0001; severe versus mild, 2.67 [2.21-3.25], <i>P</i><0.0001).</p><p><strong>Conclusion: </strong>In children with asthma in the UK, increasing disease severity was associated with increased risk of severe exacerbations, re-exacerbations, and increased HCRU and costs.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"18 ","pages":"161-171"},"PeriodicalIF":3.7,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11809225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Joint Association of Sleep Quality and Outdoor Activity with Asthma and Allergic Rhinitis in Children: A Cross-Sectional Study in Shanghai.","authors":"Ruoyu Lu, Ye Zhang, Yiting Chen, Jiajun Lyu, Rong Li, Wenhui Kang, Anda Zhao, Zidi Ning, Yabin Hu, Xiaya Lin, Shilu Tong, Zhaohui Lu, Shenghui Li","doi":"10.2147/JAA.S494662","DOIUrl":"10.2147/JAA.S494662","url":null,"abstract":"<p><strong>Purpose: </strong>Aiming to investigate the combined association of sleep quality and outdoor activity with the risk of asthma and allergic rhinitis in children.</p><p><strong>Patients and methods: </strong>16,936 children from kindergartens and primary schools in 13 administrative districts of Shanghai, China were involved in the analyses. The Children's Sleep Habits Questionnaire (CSHQ) and the International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire were respectively used to evaluate the sleep quality, allergic rhinitis and asthma. Multivariable logistic regression models were used to analyze the correlation of sleep quality, outdoor activities and their combination with children's asthma and allergic rhinitis.</p><p><strong>Results: </strong>The overall prevalence of asthma and allergic rhinitis in our sampled children were 10.2% and 17.6%, respectively. Poor sleep quality (asthma: aOR, 1.45; 95% CI: 1.23 to 1.73; allergic rhinitis: aOR, 1.16; 95% CI: 1.03 to 1.31) and low outdoor activity (asthma: aOR, 1.30; 95% CI: 1.14 to 1.49, allergic rhinitis: aOR, 1.18; 95% CI: 1.07 to 1.32) were separately associated with higher risk of asthma and allergic rhinitis, and when the two were superimposed, an additive effect (asthma: aOR, 1.76; 95% CI: 1.30 to 2.39; allergic rhinitis: aOR, 1.46; 95% CI: 1.17 to 1.82) was revealed. These associations were independent of sleep duration, but being stronger in sleep sufficiency group. And after stratification by gender, premature birth and family history of allergy, similar associations were validated in general.</p><p><strong>Conclusion: </strong>Poor sleep quality and low levels of outdoor activity, when combined, have a stronger association with asthma and allergic rhinitis than each factor independently, and this relationship is not influenced by sleep duration. Our findings highlight the need for public health interventions that simultaneously address multiple lifestyle factors to reduce the risk of allergic diseases.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"18 ","pages":"101-111"},"PeriodicalIF":3.7,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11807787/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bibliometric Analysis of Global Pediatric Research on Cow's Milk Protein Allergy.","authors":"Xiaolan Lin, Yifan Chen, Weidong Lin","doi":"10.2147/JAA.S487698","DOIUrl":"10.2147/JAA.S487698","url":null,"abstract":"<p><strong>Background: </strong>Cow's milk protein allergy (CMPA) is a prevalent food allergy in early childhood, significantly impacting the quality of life for affected children. Current palliative measures, such as specialized formula milk, offer temporary relief but are costly and fail to address the underlying issue. Thus, there is a critical need to better understand CMPA and explore new treatment options.</p><p><strong>Methods: </strong>This study employed bibliometric methods to analyze global pediatric CMPA research and identify future directions for the first time. Visual analyses were conducted using VOS Viewer and CiteSpace software.</p><p><strong>Results: </strong>A total of 2040 articles published between 2000 and 2023 showed increasing annual publications. In this field of research, the Icahn School of Medicine at Mount Sinai has made significant contributions, with the most influential articles published in the <i>Journal of Allergy and Clinical Immunology</i>. Current research emphasizes personalized therapy, probiotics, and gut microbiota in CMPA.</p><p><strong>Conclusion: </strong>Future research will focus on microbiota-related personalized treatments, promising effective clinical interventions.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"18 ","pages":"85-100"},"PeriodicalIF":3.7,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11771186/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143052563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in and Potential Mechanisms of Circulating IgA+CD27-Class-Switched Memory B Cells in Patients With Allergic Rhinitis.","authors":"Han Zheng, Shan Xu, Rui Yang, Wo-Er Jiao, Yue-Long Qiao, Jia-Yu Liu, Hui-Ming Fan, Yan-Ting Zhou, Hai-Feng Ni, Jin Chen, Yu-Qin Deng, Shi-Ming Chen","doi":"10.2147/JAA.S501775","DOIUrl":"10.2147/JAA.S501775","url":null,"abstract":"<p><strong>Background: </strong>The role of memory B cells and their subgroups in allergic rhinitis (AR) and allergen immunotherapy (AIT) remains unclear. This study aimed to investigate the characteristics of memory B cells in the circulation of patients with AR and those undergoing AIT, as well as their clinical significance.</p><p><strong>Methods: </strong>This study involved a cohort comprising 32 healthy control subjects, 39 individuals diagnosed with AR, and 31 AR patients who had received AIT for over one year. Visual analog scale (VAS) scores were used for symptom assessment, and the serum concentrations of immunoglobulins and cytokines were quantified. This study evaluated alterations in the proportions of peripheral blood memory B cells and their subpopulations, plasma cells, and various T-cell subsets across the three participant groups.</p><p><strong>Results: </strong>The proportion of IgA+CD27- class-switched memory B cells in the AR group significantly decreased compared to the control group, but significantly increased following AIT (P < 0.05). In AR patients, circulating IgA+CD27- class-switched memory B cells were significantly positively correlated with Treg cells, IL-10, and IL-4 and significantly negatively correlated with IFN-γ, total IgE, sIgE, and VAS scores (P < 0.05). After AIT, the number of circulating IgA+CD27- class-switched memory B cells in AR patients was significantly positively correlated with the number of Treg cells and IL-10 and significantly negatively correlated with the VAS score (P < 0.05).</p><p><strong>Conclusion: </strong>The IgA+CD27- class-switched memory cell subset in human peripheral blood may serve as a potential biomarker for evaluating AR symptoms and treatment efficacy. Its mechanism may be associated with interactions between T and B cells.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"18 ","pages":"69-83"},"PeriodicalIF":3.7,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11766316/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-Pharmaceutical Interventions May Attenuate Acute Exacerbations of Asthma: Experience During the COVID-19 Pandemic in Taiwan.","authors":"Chun-Yu Lin, Chiung-Hung Lin, Yu-Lun Lo, Chun-Yu Lo, Hung-Yu Huang, Meng-Heng Hsieh, Yueh-Fu Fang, Tsu-Chuan Li, Shu-Min Lin, Yu-Tung Huang, Po-Jui Chang, Horng-Chyuan Lin","doi":"10.2147/JAA.S488352","DOIUrl":"10.2147/JAA.S488352","url":null,"abstract":"<p><strong>Background: </strong>Non-pharmaceutical interventions (NPIs) were widely used during the coronavirus disease 2019 (COVID-19) pandemic, however their impact on acute asthma exacerbations (AEs) is not well studied.</p><p><strong>Methods: </strong>We had retrospectively collected patients with asthma AEs between 2019 and 2020 and retrieved data from the Chang Gung Research Database, including clinical manifestations, medications, pulmonary function, clinic and emergency department visits and hospitalizations.</p><p><strong>Results: </strong>A total of 39,108 adult patients with asthma were enrolled, of whom 1502 were eligible for analysis. The prevalence of acute AEs significantly decreased throughout 2020 compared with 2019 after implementation of the NPI policy. The patients were categorized into four groups: Group 1, acute AEs in 2019 with influenza infection (n=692); Group 2: acute AEs in 2019 without influenza infection (n=328); Group 3: acute AEs in 2020 with influenza infection (n=268); Group 4: acute AEs in 2020 without influenza infection (n=214). The patients in group 4 were significantly older (73.3±29.1 vs 65.5±29.2, 69.7±26.2 years, p<0.01) and had significantly worse forced expiratory volume in one second/forced vital capacity ratio (70.5±13.9 vs 79.6±15.5, 72.9±18.0, p<0.01) than those in group 1 and 2, and the highest rate of oral corticosteroid prescriptions (17%, p<0.01). The patients in group 3 and 4 had significantly lower rates of oxygen therapy, ventilator use and mortality at 3 and 12 months of follow-up than those in group 1 and 2.</p><p><strong>Conclusion: </strong>The use of NPIs during the COVID-19 pandemic in Taiwan may reduce the frequency and severity of asthma AEs. This may provide some cost-effective strategies to attenuate acute asthma AEs.</p>","PeriodicalId":15079,"journal":{"name":"Journal of Asthma and Allergy","volume":"18 ","pages":"59-67"},"PeriodicalIF":3.7,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11760758/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}